By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


National Cancer Institute (NCI) 

NCI Public Inquiries Office
Building, 31, Room 10A03
31 Center Drive, MSC 2

Bethesda  Maryland  20892-2580  U.S.A.
Phone: 301-435-3848 Fax:



Maxygen, Inc. 

Genzyme General 

PanVera LLC 

Panacos Pharmaceuticals Inc.  Panacos has a CRADA with leading scientists at the National Cancer Institute to study the mechanism of HIV maturation inhibitors and to discover new antiviral drugs.

Company News
President's Cancer Moonshot Initiative Fosters Breakthrough Collaboration Between The Colon Cancer Alliance, Smart Patients, And The Colon Cancer Alliance 6/30/2016 9:21:36 AM
Cellectar Biosciences  (NVLT) Announces Results Of NCI-Sponsored Study Of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer 6/23/2016 7:53:47 AM
Kite Pharma (KITE) Expands Development Of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers In Partnership With The NCI 6/20/2016 10:45:28 AM
Pharmaron LLC Joins The NCI’s Chemical Biology Consortium To Fight Against Cancer 6/14/2016 8:18:15 AM
ASCO2016: Kite Pharma (KITE)/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma 6/6/2016 9:23:17 AM
Former NCI And NIH Director Dr. Harold Varmus Joins The International Biomedical Research Alliance Board 6/2/2016 10:43:16 AM
Kite Pharma (KITE) Cancer Therapy Responses in Solid Tumors Continued in Small Trial, NCI Review Halts Patient Enrollment 4/18/2016 6:41:09 AM
Altor BioScience Corporation Partners With The NCI To Further Develop Altor’s ALT-803 And ALT-801 Cancer Immunotherapeutics 4/11/2016 8:45:29 AM
NantBioscience Partner With The NantKwest To Further Develop Recombinant NK Cells And Monoclonal Antibodies As Monotherapies And Combination Cancer Immunotherapies 4/5/2016 8:13:08 AM
RareCyte Announces CRADA With NCI In Immunology/Oncology 3/14/2016 11:58:04 AM